ライフサイエンスコーパス: alpha-fetoprotein

1 P=.01 for alkaline phosphatase, P<.0001 for alpha-fetoprotein).

2 to a clinical diagnosis and was superior to alpha-fetoprotein.

3 respective of tumor burden or serum level of alpha-fetoprotein.

4 (KO) tumors that express increased levels of alpha-fetoprotein.

5 ted by MELD score, HCC size, HCC number, and alpha-fetoprotein.

6 lar invasion, metastasis, serum albumin, and alpha-fetoprotein.

7 ed expression of fetal liver genes including alpha-fetoprotein.

8 d concomitantly with increased expression of alpha-fetoprotein.

9 arly hepatic neoplasia and increase in serum alpha-fetoprotein.

10 per cm increase [1.04-1.11]; p<0.0001), log alpha-fetoprotein (1.10 per unit increase [1.02-1.20]; p

11 Of patients with an elevated pretreatment alpha-fetoprotein, 85% were found to have declining alph

12 to the homogeneous liquid-phase detection of alpha-fetoprotein, a common tumor marker, the system sho

13 calization of beta-catenin and expression of alpha-fetoprotein, a prognostic marker of hepatocellular

14 alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein (AFAFP) levels or abnormalities visual

15 Median alpha fetoprotein (AFP) at diagnosis and pre-LDLT were 7

16 an 3 years, 3-7 years, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lo

17 aximal tumor diameter of 3 to 5 cm and serum alpha fetoprotein (AFP) greater than 100 ng/mL at transp

18 ferase (AST)-platelet ratio index (APRI) and alpha fetoprotein (AFP) in Ghana.

19 Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm,

20 A technique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups.

21 s carcinoembryonic antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) we

22 immunodominant and subdominant epitopes from alpha fetoprotein (AFP), restricted by HLA-A*0201, which

23 High alpha-fetoprotein (AFP) > 1,000 ng/mL is associated with

24 Elevated alpha-fetoprotein (AFP) >/= 10,000 ng/mL was associated

25 (hazard ratio [HR], 3.1; P = 0.005) and with alpha-fetoprotein (AFP) >= 100 ng/mL at LT (HR, 2.4; P =

26 Most strikingly, patients with an alpha-fetoprotein (AFP) >=10 ng/mL and having used sirol

27 In multivariate analysis, only alpha-fetoprotein (AFP) >=200 ng/mL (P = 0.006) and larg

28 ubanalysis for patients with a high level of alpha-fetoprotein (AFP) (>100 ng/dL) was conducted.

29 ic marker A6 (94.57% +/- 0.033%), as well as alpha-fetoprotein (AFP) (75.92% +/- 0.071%).

30 motherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonad

31 Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadot

32 We used two model biomarkers [alpha-fetoprotein (AFP) and cancer antigen 125 (CA125)]

33 of this study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombi

34 her levels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alanine amino

35 HCC surveillance with alpha-fetoprotein (AFP) and ultrasonography has been rec

36 ce recommendation through the examination of alpha-fetoprotein (AFP) and ultrasound for patients at r

37 We identified alpha-fetoprotein (AFP) and ultrasound tests performed f

38 Serum levels of alpha-fetoprotein (AFP) are influenced not only by the p

39 In addition, we have identified the alpha-fetoprotein (AFP) as a novel downstream target of

40 Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis.

41 after accounting for etiology of cirrhosis, alpha-fetoprotein (AFP) at liver transplant, tumor diame

42 ter Transplant (RETREAT), which incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), m

43 accurate quantitation of biomarkers such as alpha-fetoprotein (AFP) can be a key aspect of early sta

44 her the HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an

45 We previously showed that mouse alpha-fetoprotein (AFP) enhancer 3 activity is highly re

46 pression under the control of an albumin and alpha-fetoprotein (AFP) enhancer and promoter (AFP-Notch

47 Although alpha-fetoprotein (Afp) falls into this class of genes,

48 Aberrant expression of the alpha-fetoprotein (AFP) gene is a diagnostic tumor marke

49 The alpha-fetoprotein (AFP) gene is expressed abundantly in

50 nd core promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

51 analyzed methylation of the rat albumin and alpha-fetoprotein (AFP) genes by hydridizing labeled cDN

52 For decades, alpha-fetoprotein (AFP) has been used as a differentiati

53 ng the neutrophil-lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurr

54 formance status, Child-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual surviva

55 orted to be more sensitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among th

56 alpha-Fetoprotein (AFP) independently predicted tumor re

57 Alpha-fetoprotein (AFP) is a biomarker for hepatocellula

58 Serum alpha-fetoprotein (AFP) is a biomarker for hepatocellula

59 The L3 isoform of alpha-fetoprotein (AFP) is a specific marker for hepatoc

60 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intri

61 alpha-fetoprotein (AFP) is an oncofetal Ag that is highl

62 Alpha-fetoprotein (AFP) is considered to be an indicator

63 for sensitive detection of cancer biomarker alpha-fetoprotein (AFP) is described that uses a graphen

64 alpha-Fetoprotein (AFP) is frequently used as a diagnost

65 ent and expression of the hepatoblast marker alpha-fetoprotein (Afp) is lost.

66 Alpha-fetoprotein (AFP) is often expressed at high level

67 Although serum alpha-fetoprotein (AFP) is often used to detect hepatoce

68 noma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose.

69 Alpha-fetoprotein (AFP) is widely used as a surveillance

70 identified substantial necrosis, high serum alpha-fetoprotein (AFP) level (>100 ng/mL), and Barcelon

71 ent cohort of 721 patients (542 men), median alpha-fetoprotein (AFP) level at the time of LT was 8.3

72 (BCLC) staging system, tumor size, and serum alpha-fetoprotein (AFP) level were investigated using Co

73 cic lymph node metastases and a rising serum alpha-fetoprotein (AFP) level.

74 Nonetheless, serial measurement of alpha-fetoprotein (AFP) levels in serum and hepatic ultr

75 (ADI) in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine level

76 lated with tumor histology and pretransplant alpha-fetoprotein (AFP) levels.

77 marker testing disclosed a slightly elevated alpha-fetoprotein (AFP) of 12.3 ug/L (upper limit of nor

78 s to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular ca

79 Alpha-fetoprotein (AFP) represents a classical model sys

80 Our group has shown that a rising natural alpha-fetoprotein (AFP) slope (NAS) correlates with tumo

81 pressor p53 in the regulation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

82 osorbent assay was developed to detect human alpha-fetoprotein (AFP) using carbon dots (C-Dots).

83 In 17 patients the baseline serum alpha-fetoprotein (AFP) was >or= 1,000 ng/mL; in four of

84 The AUC value for alpha-fetoprotein (AFP) was 0.80 (0.74-0.87) compared to

85 To use the device under optimal conditions, alpha-fetoprotein (AFP) was detected at a limit of detec

86 Remarkably, expression of alpha-fetoprotein (AFP) was highly correlated with the m

87 Levels of human alpha-fetoprotein (AFP) were monitored in the serum of a

88 the hepatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with the lowest concentration of

89 adhesion molecule (EpCAM)(+) HCC cells from alpha-fetoprotein (AFP)(+) tumors with cancer stem/proge

90 ls with activated Wnt signaling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive

91 As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocel

92 reased hepatic associated gene expression of alpha-fetoprotein (AFP), Albumin (Alb), Glucose-6-phosph

93 , with some potential advantages compared to alpha-fetoprotein (AFP), but its role in the context of

94 biomarkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), and

95 kers carbohydrate antigen 19-9 (CA 19-9) and alpha-fetoprotein (AFP), commonly used to help in the di

96 The fetal hepatocytes expressed alpha-fetoprotein (AFP), cytokeratin (CK) 19, albumin, a

97 sed overlapping peptides spanning the entire alpha-fetoprotein (AFP), glypican-3 (GPC-3), melanoma-as

98 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations.

99 tive for markers of visceral endoderm (DAB2, alpha-fetoprotein (AFP), HNF4).

100 , a factor required for HSC homing, and also alpha-fetoprotein (AFP), indicating that they are fetal

101 ed hepatocellular carcinoma (HCC) biomarkers alpha-fetoprotein (Afp), insulin-like growth factor 2 (I

102 They are negative for alpha-fetoprotein (AFP), intercellular adhesion molecule

103 trongly associated with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis a

104 Serum alpha-fetoprotein (AFP), normally highly expressed in th

105 10 mRNA expression was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) sta

106 With this approach, an aptamer specific to alpha-fetoprotein (AFP), which is a biomarker for liver

107 ted polymer (MIP) for trace level sensing of alpha-fetoprotein (AFP), which is a well know cancer bio

108 sodium (MELD-Na), tumour burden score (TBS), alpha-fetoprotein (AFP), year of transplantation, underl

109 ltrasensitive detection of cancer biomarker, alpha-fetoprotein (AFP).

110 developmental repression of the tumor marker alpha-fetoprotein (AFP).

111 d for direct and ultrasensitive detection of alpha-fetoprotein (AFP).

112 stic implication by determining the level of alpha-fetoprotein (AFP).

113 n (CK) 19, albumin +/-, and are negative for alpha-fetoprotein (AFP).

114 is of HCC in Japanese patients compared with alpha-fetoprotein (AFP).

115 ssion of the transcription factor SOX-17 and alpha-fetoprotein (AFP).

116 protein biomarker panel [APOH, ORM2, C3, and alpha-fetoprotein (AFP)] has proven to outperform AFP, t

117 osed total tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL) score.

118 occurrence as well as patients with negative alpha-fetoprotein (AFP; n = 1), resulting in 24 patients

119 2 recently identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC).

120 tumor-associated self-antigens (for example, alpha-fetoprotein [AFP]).

121 of antibodies specific for epithelial cells (alpha-fetoprotein [AFP], albumin [ALB], pancytokeratin [

122 e Panel recommended measuring three markers (alpha-fetoprotein [AFP], human chorionic gonadotropin [h

123 The vast majority of alpha fetoprotein(+), albumin(+), cytokine-19(+), and E-

124 erum alpha-fetoprotein and ferritin or serum alpha-fetoprotein alone, including four with coagulopath

125 albumin gene family is comprised of albumin, alpha-fetoprotein, alpha-albumin (afamin), and the more

126 encode the serum transport proteins albumin, alpha-fetoprotein, alpha-albumin, and vitamin D-binding

127 fibrinogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential feature for functional H

128 te that this enhancer region is required for alpha-fetoprotein and albumin activation early in liver

129 lls were analyzed by immunocitochemistry for alpha-fetoprotein and albumin expression, qPCR for hepat

130 strate that RNA polymerase II loading on the alpha-fetoprotein and albumin promoters is reduced in th

131 enriched (45-70%) for cells that express the alpha-fetoprotein and albumin proteins.

132 a member of a cluster that includes albumin, alpha-fetoprotein and alpha-albumin genes.

133 f these genes, particularly that of albumin, alpha-fetoprotein and alpha-albumin, and their liver-spe

134 Serum and CSF alpha-fetoprotein and beta-human chorionic gonadotropin

135 erum and cerebrospinal fluid (CSF) levels of alpha-fetoprotein and beta-subunit of human chorionic go

136 Plasma levels of alpha-fetoprotein and c-MET were associated with poor ou

137 d higher than normal concentrations of serum alpha-fetoprotein and ferritin or serum alpha-fetoprotei

138 The prognostic information provided by alpha-fetoprotein and human chorionic gonadotrophin in t

139 Serum tumor markers alpha-fetoprotein and human chorionic gonadotrophin were

140 , 134-142 mEq/L [134-142 mmol/L]), and serum alpha-fetoprotein and human chorionic gonadotropin level

141 Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of T

142 logistic regression selected combined serum alpha-fetoprotein and portal flow (F (p) ) skewness (are

143 iated with induction of the human HCC marker alpha-fetoprotein and the stem cell marker CD133.

144 en second-trimester levels of maternal serum alpha-fetoprotein and the subsequent risk of SIDS.

145 lutamyl transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt expor

146 tients with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin)

147 nd-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were

148 , secreted hepatic proteins such as Albumin, Alpha Fetoprotein, and Fibrinogen, metabolized ammonia,

149 l expression/coexpression of DCAMKL-1, CK19, alpha-fetoprotein, and active c-Src.

150 iated liver phenotype: albumin, transferrin, alpha-fetoprotein, and alpha1-antitrypsin.

151 with the expression of biliary cytokeratins, alpha-fetoprotein, and c-Met by FIHC.

152 those of beta-human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase.

153 tion expressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated into hepatocy

154 igh level expression of active beta-catenin, alpha-fetoprotein, and SOX9, suggesting that DCLK1 overe

155 total bilirubin, albumin, prothrombin time, alpha-fetoprotein, and tumor number, which were incorpor

156 tribution; levels of bilirubin, albumin, and alpha-fetoprotein; and WHO/EASL response rate predicted

157 leaved K18, glutathione S-transferase alpha, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbit

158 gical stage, tumour histology, and levels of alpha-fetoprotein at diagnosis to receive risk-adapted t

159 alpha-Fetoprotein, beta-human chorionic gonadotropin, an

160 tients with HBV had larger tumors and higher alpha-fetoprotein but less satellites and macrovascular

161 ibiting cytoplasmic/nuclear beta-catenin and alpha-fetoprotein but not CK19, HNF1beta, or Trop-2.

162 4, cytokeratin 19 (CK19), transthyretin, and alpha-fetoprotein by day 7, and expressed CK18, HNF-4, a

163 M+, c-met+, SSEA-4+, CK18+, CK19+, albumin-, alpha-fetoprotein-, CD44h+, and vimentin+.

164 not significantly different among the three alpha-fetoprotein classes (P = 0.493).

165 ed according to randomising centre and serum alpha-fetoprotein concentration (<400 ng/mL and >/=400 n

166 , extrahepatic spread, or both; and baseline alpha-fetoprotein concentration.

167 anced hepatocellular carcinoma and increased alpha-fetoprotein concentrations have poor prognosis.

168 Group (ECOG) performance statuses of 0 or 1, alpha-fetoprotein concentrations of 400 ng/mL or greater

169 a from REACH (NCT01140347) for patients with alpha-fetoprotein concentrations of 400 ng/mL or greater

170 s with advanced hepatocellular carcinoma and alpha-fetoprotein concentrations of 400 ng/mL or higher.

171 n patients with hepatocellular carcinoma and alpha-fetoprotein concentrations of at least 400 ng/mL w

172 ction was assessed by expression of albumin, alpha-fetoprotein, cytochrome P4502E1, cytokeratin-18, t

173 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprot

174 re alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all o

175 tumors and embryonal carcinomas positive for alpha-fetoprotein, cytokeratin AE1/AE3, and CD30.

176 d CaM kinase-like-1 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-M

177 heral zones were simultaneously positive for alpha-fetoprotein, cytokeratin-19, and c-kit, indicating

178 lls express the classical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 inte

179 ever, when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothrombin, and GP7

180 leukemia (n = 1), and 1 patient treated with alpha-fetoprotein-directed CAR T cells for hepatocellula

181 A raised maternal serum level of alpha-fetoprotein during the second trimester of pregnan

182 e replaced the endodermal enhancers with the alpha-fetoprotein endodermal enhancers (H19Afp).

183 ressing Cre-recombinase under control of the alpha fetoprotein enhancer and albumin promoter.

184 To directly examine whether the alpha-fetoprotein enhancer region could regulate the alb

185 nder the control of the albumin promoter and alpha-fetoprotein enhancer to ablate Jag1 in hepatoblast

186 he expression of vimentin, beta-III tubulin, alpha-fetoprotein, eomesodermin, HEB, ARNT, and FoxD3 as

187 rial abdominal computed tomography and serum alpha-fetoprotein every 6 months.

188 e performed using ultrasound with or without alpha-fetoprotein every 6 months.

189 oval cell proliferation and a lower level of alpha-fetoprotein expression as compared with control an

190 ogs induced albumin expression and decreased alpha-fetoprotein expression in HepG2 cells, which sugge

191 e basis of the similarities between Gpc3 and alpha-fetoprotein expression in the liver, we reasoned t

192 F-1 expression caused a dramatic decrease in alpha-fetoprotein expression, implying impaired oval cel

193 e staining (absent or diffuse), and variable alpha-fetoprotein expression.

194 ok 2, spalt-like transcription factor 4, and alpha-fetoprotein expression; and high coordinated expre

195 The albumin and alpha-fetoprotein genes are adjacent and express closely

196 ts (HR, 0.3; 95% CI, 0.2-0.7; P = 0.003) and alpha-fetoprotein > 100 ng/mL (HR, 2.5; 95% CI, 1.1-5.0,

197 the downstaging group included pretreatment alpha-fetoprotein >/=1,000 ng/mL (multivariate hazard ra

198 redicting treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL.

199 r disease (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.

200 alyses identified age <65 years (P = 0.038), alpha-fetoprotein >200 ng/mL (P = 0.04), and vascular in

201 sorafenib, or ramucirumab (for patients with alpha-fetoprotein >= 400 ng/mL), or atezo + bev where pa

202 ular invasion, exceeding Milan criteria, and alpha-fetoprotein>200 ng/mL.

203 ize of tumors, presence of metastases, serum alpha-Fetoprotein, hepatitis serologies, severity of hep

204 They also expressed alpha-fetoprotein, hepatocyte nuclear factor-4a, and a m

205 ted clinical diagnostic application, such as alpha-fetoprotein in liver carcinoma, and kallikreins 6

206 evaluate the prognostic usefulness of serum alpha-fetoprotein in patients with well-compensated cirr

207 cificity of des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular car

208 ted on a clinically relevant assay to detect alpha-fetoprotein, in which a 42-fold enhancement to sen

209 The proposed Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score was the bes

210 (AST)/alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assess

211 Alpha-fetoprotein is a tumor marker that has been used f

212 Alpha-fetoprotein is the most widely used tumor marker,

213 zard ratio, 1.61; 95% CI: 1.3-2.1) and serum alpha-fetoprotein level >/=455 ng/mL (hazard ratio, 2.15

214 Patients with larger (3-5 cm) tumors, serum alpha-fetoprotein level >/=455 ng/mL, or a MELD score >/

215 a cirrhotic liver in the presence of a serum alpha-fetoprotein level >400 ng/mL also is diagnostic.

216 An alpha-fetoprotein level >500 ng/mL predicted poorer outc

217 l undifferentiated histology; elevated serum alpha-fetoprotein level (>100 ng/mL); a complete resecti

218 s showed significant effects of pretreatment alpha-fetoprotein level (P = .03) and ADC ratio (P < .00

219 rnational normalized ratio greater than 1.1, alpha-fetoprotein level greater than 20 ng/mL, multiple

220 A preablative serum alpha-fetoprotein level higher than 200 ng/mL (hazard ra

221 priate candidates for liver transplantation; alpha-fetoprotein level limitations should be incorporat

222 mal range, 13-60 U/L [0.21-1.0 mukat/L]), an alpha-fetoprotein level of 3.81 ng/ mL (normal range, 0-

223 ory studies were significant for an elevated alpha-fetoprotein level of 7051 ng/ml and mild anemia.

224 vascular invasion, extrahepatic disease, and alpha-fetoprotein level to best supportive care plus ora

225 were slightly depressed at 121,000 muL, and alpha-fetoprotein level was 89 mug/L.

226 was achieved in 10 patients (83.3%), and the alpha-fetoprotein level was also decreased to normal in

227 erum markers for ovarian cancer were normal (alpha-fetoprotein level, 1.6 microg/L; Ca-125 level, 15

228 clinical factors (age, gender, preoperative alpha-fetoprotein level, hepatitis serology, number of t

229 tingly, the two most recent models combining alpha-fetoprotein level, number of nodules, and size of

230 for study site, age, sex, Child-Pugh score, alpha-fetoprotein level, tumor burden, and HCC treatment

231 Serum alpha fetoprotein levels were below 10 ng/mL in all 4 pa

232 oenvironment also correlated with high serum alpha-fetoprotein levels (P < 0.001), macrovascular inva

233 -Pugh scores (P = .003), higher pretreatment alpha-fetoprotein levels (P = .04), and a greater number

234 It is unknown whether alpha-fetoprotein levels also predict the risk of SIDS.

235 tion between second-trimester maternal serum alpha-fetoprotein levels and the risk of SIDS, which may

236 Patients were followed with CT scan and alpha-fetoprotein levels every 3 months for 2 years post

237 etoprotein, 85% were found to have declining alpha-fetoprotein levels from a pretreatment mean of 140

238 l symptoms, normal eye movements, and normal alpha-fetoprotein levels in some individuals.

239 ence, 2.7 per 10,000 births among women with alpha-fetoprotein levels in the lowest quintile and 7.5

240 and increased aspartate aminotransferase and alpha-fetoprotein levels were associated with HCC (p < 0

241 otransferase/alanine aminotransferase ratio, alpha-fetoprotein levels, and IL28B single-nucleotide po

242 talian Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replac

243 markers of tumor aggressiveness (high serum alpha-fetoprotein levels, P = 0.038; satellite nodules,

244 [LPA(16:0)], where it correlated with plasma alpha-fetoprotein levels.

245 xtent of cellular differentiation, and serum alpha-fetoprotein levels.

246 esence of a relatively stable genome and low alpha-fetoprotein levels.

247 when inserted into the normally nonimprinted alpha fetoprotein locus.

248 in the genome, downstream of H19 and at the alpha-fetoprotein locus on chromosome 5.

249 95% confidence interval [CI], 1.03-1.30) and alpha-fetoprotein < 20 ng/mL (OR, 1.90; 95% CI, 1.12-3.2

250 hosis should be screened with ultrasound and alpha-fetoprotein measurement every 6 months.

251 rveillance for HCC is by ultrasonography and alpha-fetoprotein measurements every 6-12 months.

252 ariables (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criteria status, and radiologic

253 logical response to loco-regional therapies, alpha-fetoprotein modification, inflammatory markers, an

254 eal patients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of mali

255 d time from primary resection to recurrence, alpha-fetoprotein more than 100 ng/mL at recurrence, rec

256 ellite nodules, albumin less than 3.5 gm/dL, alpha-fetoprotein more than 100 ng/mL, and any vascular

257 60 years, tumor size larger than 7.0 cm, and alpha-fetoprotein more than 100 ng/mL.

258 FGF19 transgenic mice had elevated hepatic alpha-fetoprotein mRNA as early as 2 months of age, and

259 er RNA (mRNA) levels and reduced Albumin and Alpha-fetoprotein mRNA levels, indicating that they are

260 eatures were greatly elevated maternal serum alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetopr

261 ype (albumin-positive, transferrin-positive, alpha-fetoprotein-negative) and are able to proliferate

262 n of neuronal cellular adhesion molecule and alpha-fetoprotein, neuroectodermal, and endodermal marke

263 Only tumor variables of alpha-fetoprotein, number, total diameter, microvascular

264 inal nonseminoma (group A) and elevations of alpha-fetoprotein of 100 ng/mL or greater or of human ch

265 years), especially when combined with serum alpha fetoprotein or tumor staging.

266 ction of either one liver cancer marker, the alpha-fetoprotein, or the detection of Hepatitis C Virus

267 dent of BCLC ( P < .0001), CTP ( P < .0001), alpha-fetoprotein ( P < .0001), geographical origin ( P

268 e HIV-positive included CTP ( P = .0071) and alpha-fetoprotein ( P < .0001).

269 d with the standard HCC serum protein marker alpha fetoprotein (P = 0.57).

270 eterogeneous recurrence risk, dependent upon alpha-fetoprotein (P = 0.026) and tumor number (P = 0.02

271 almitic acid, suggesting that the high serum alpha-fetoprotein phenotype of G1, associated with the k

272 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cells within tumors were hepa

273 striking increase in the number of c-kit and alpha-fetoprotein-positive progenitors, without altering

274 and were predominantly H.4 antigen-positive, alpha-fetoprotein-positive, and OV6-negative.

275 Neonatal alpha-fetoprotein prevents circulating estrogens from ac

276 under age 40; p < 0.001), with greater serum alpha-Fetoprotein production (median level: HBV-1000 ng/

277 in activation early in liver development and alpha-fetoprotein reactivation during liver regeneration

278 The best alpha-fetoprotein reduction ranged from 32% to 95%.

279 the level of Gpc3 induction is controlled by alpha-fetoprotein regulator 2 (Afr2).

280 f the albumin gene family that we have named Alpha-fetoprotein Related Gene (ARG) since it exhibits g

281 sful down-staging is predicted by wait time, alpha-fetoprotein response to LRT, and tumor burden and

282 ivariate predictors of down-staging included alpha-fetoprotein response to LRT, pathologic tumor numb

283 is B found no survival benefit with periodic alpha-fetoprotein screening.

284 accessing the brain, therefore, to overcome alpha-fetoprotein sequestration of E2, estrogen replacem

285 An alpha-fetoprotein serum level of 100 ng/mL identified by

286 Patients were subdivided according to alpha-fetoprotein serum levels (i.e., normal </= 20 ng/m

287 Alpha-fetoprotein serum levels have no prognostic meanin

288 ng persons with chronic HBV semiannually for alpha-fetoprotein since 1982.

289 factors of posttransplant survival included alpha-fetoprotein, size of the largest tumor, number of

290 apid loss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver c

291 Of 11 patients with elevated alpha-fetoprotein, three (27%) had decreases of 50% or m

292 rimester quadruple screening (measurement of alpha-fetoprotein, total human chorionic gonadotropin, u

293 erm has recently been shown to interact with alpha-fetoprotein transcription factor and repress chole

294 cPR included a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval f

295 ity of California at San Francisco criteria, alpha-fetoprotein, up-to-7 criteria, TTV, and platelet c

296 alpha-fetoprotein values were not exclusionary.

297 Increased serum alpha-fetoprotein was a negative prognostic variable.

298 An 8-mer peptide (EMTOVNOG) derived from alpha-fetoprotein was compared with tamoxifen for activi

299 Human alpha-fetoprotein was never expressed, but in some mice,

300 Combined expression of SCD and alpha-fetoprotein were associated with outcomes of patie